{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:55:21Z","timestamp":1791428121228,"version":"4.3.3"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009848","name":"Tower Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","award":["P01 CA244118"],"award-info":[{"award-number":["P01 CA244118"]}],"id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","award":["P30 CA016042"],"award-info":[{"award-number":["P30 CA016042"]}],"id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013041","name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016206","name":"Clinical and Translational Science Institute, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["9402905"],"award-info":[{"award-number":["9402905"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20170022275"],"award-info":[{"award-number":["20170022275"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20100111973"],"award-info":[{"award-number":["20100111973"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["10279021"],"award-info":[{"award-number":["10279021"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20160046716"],"award-info":[{"award-number":["20160046716"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20170008962"],"award-info":[{"award-number":["20170008962"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["7250291"],"award-info":[{"award-number":["7250291"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["10106611"],"award-info":[{"award-number":["10106611"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20160340407"],"award-info":[{"award-number":["20160340407"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20140004112"],"award-info":[{"award-number":["20140004112"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20170343552"],"award-info":[{"award-number":["20170343552"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","award":["20170248603"],"award-info":[{"award-number":["20170248603"]}],"id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["15\/612,657"],"award-info":[{"award-number":["15\/612,657"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["PCT\/US18\/36052"],"award-info":[{"award-number":["PCT\/US18\/36052"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CA233259"],"award-info":[{"award-number":["CA233259"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CA006973"],"award-info":[{"award-number":["CA006973"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006535","name":"Entertainment Industry Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006535","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014959","name":"Tizona Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["3M"],"award-info":[{"award-number":["3M"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA009120"],"award-info":[{"award-number":["T32-CA009120"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA142779"],"award-info":[{"award-number":["R01 CA142779"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016765","name":"Jounce Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ccell.2020.08.005","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:43:42Z","timestamp":1599734622000},"page":"500-515.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":364,"title":["Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma"],"prefix":"10.1016","volume":"38","author":[{"given":"Catherine S.","family":"Grasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykola","family":"Onyshchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Abril-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Ross-Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wind-Rotolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Champhekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egmidio","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis Y.","family":"Torrejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Sanghoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Puig-Saus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Vega-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Martignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sharfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Urba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador Martin","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew M.","family":"Pardoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valsamo","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Topalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Velculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Kalbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2020.08.005_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Abril-Rodr\u00edguez","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2020.08.005_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2020.08.005_bib3","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib5","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2020.08.005_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","article-title":"The IFN gamma receptor: a paradigm for cytokine receptor signaling","volume":"15","author":"Bach","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ccell.2020.08.005_bib7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2020.08.005_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib10","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.08.005_bib11","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T\u00a0cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.08.005_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2020.08.005_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2020.08.005_bib14","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/0962280215577111","article-title":"A comparative review of methods for comparing means using partially paired data","volume":"26","author":"Guo","year":"2017","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T\u00a0cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T\u00a0cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2020.08.005_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2020.08.005_bib25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib28","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/0008-5472.CAN-16-2680","article-title":"Broad and conserved immune regulation by genetically heterogeneous melanoma cells","volume":"77","author":"Neubert","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib31","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI95351","article-title":"beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas","volume":"128","author":"Nsengimana","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2020.08.005_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic virotherapy promotes intratumoral T\u00a0cell infiltration and improves anti-PD-1 immunotherapy","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.08.005_bib37","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib38","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib40","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2020.08.005_bib41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib42","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1158\/1078-0432.CCR-19-0402","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T\u00a0cells (Tregs) in human cancers-response","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2020.08.005_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2020.08.005_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-8-39","article-title":"Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032","volume":"8","author":"Sondergaard","year":"2010","journal-title":"J.\u00a0Transl Med."},{"key":"10.1016\/j.ccell.2020.08.005_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2020.08.005_bib50","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2020.08.005_bib51","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2020.08.005_bib52","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming genetically-based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib53","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2020.08.005_bib55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41573-019-0043-2","article-title":"Pharmacological modulation of nucleic acid sensors\u2014therapeutic potential and persisting obstacles","volume":"18","author":"Vanpouille-Box","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2020.08.005_bib56","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2020.08.005_bib57","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2020.08.005_bib58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N.\u00a0Engl. J. Med."}],"updated-by":[{"DOI":"10.1016\/j.ccell.2020.11.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000}}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820304165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610820304165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:04:45Z","timestamp":1778817885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610820304165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1535610820304165"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2020.08.005","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2020.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}